(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 June 2017 (15.06.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/100236 A8

(51) International Patent Classification:
A61K 31/713 (2006.01) *A61P 7/04* (2006.01)
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2016/065245

(22) International Filing Date:
7 December 2016 (07.12.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/264,013	7 December 2015 (07.12.2015)	US
62/315,228	30 March 2016 (30.03.2016)	US
62/366,304	25 July 2016 (25.07.2016)	US
62/429,241	2 December 2016 (02.12.2016)	US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(72) Inventors: **AKINC, Akin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **SORENSEN, Benny**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **GARG, Pushkal**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **ROBBIE, Gabriel**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(74) Agents: **ZACHARAKIS, Maria Laccotripe** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
20 July 2017

(15) Information about Correction:
see Notice of 20 July 2017

(54) Title: METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER

(57) Abstract: The invention relates to iRNA, *e.g.,* double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, *e.g.,* dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, *e.g.,* a bleeding disorder, such as a hemophilia.

WO 2017/100236 A8